Form 4: Immuneering Corp CEO Boosts Stake with Significant Stock Purchases

Immuneering Corp's President and CEO, Benjamin J. Zeskind, has increased his direct beneficial ownership in the company through two open market purchases of Class A Common Stock in early July 2025.

Summary

• Benjamin J. Zeskind, who serves as President and CEO, Director, and a 10% Owner of Immuneering Corp (IMRX), acquired additional shares of the company's Class A Common Stock.
• On July 1, 2025, Zeskind purchased 2,985 shares of Class A Common Stock at a weighted average price of $3.3792 per share, with individual trade prices ranging from $3.35 to $3.41.
• On July 2, 2025, he acquired an additional 7,015 shares of Class A Common Stock at a weighted average price of $3.5342 per share, with individual trade prices ranging from $3.45 to $3.64.
• Following these transactions, Zeskind's direct beneficial ownership in Immuneering Corp increased to 2,312,852 shares.
• Additionally, Zeskind indirectly holds 894,927 shares of Class A Common Stock through the Benjamin J. Zeskind 2020 Family Trust, where his spouse, Lisa Schwartz, serves as the sole trustee.

Sentiment

Score: 7

Explanation: The sentiment is positive because a key insider, the CEO and a 10% owner, is increasing his direct stake in the company, signaling confidence in its future performance and aligning his interests with shareholders.

Positives

• A key insider, the President and CEO who is also a Director and 10% Owner, is increasing his direct stake in the company, signaling strong confidence in its future prospects.
• The purchases demonstrate a direct financial commitment from top management, aligning their interests with those of shareholders.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future outlook, as it is solely a report of insider transactions.

Management Comments

• This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.35 to $3.41. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price. (Referring to July 1, 2025 transaction)
• This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.45 to $3.64. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price. (Referring to July 2, 2025 transaction)

Industry Context

Insider purchases, particularly by a CEO and significant owner, are generally viewed positively by the market as they signal management's confidence in the company's prospects. In the biotechnology or pharmaceutical industry, where Immuneering Corp likely operates given its name, such confidence can be particularly impactful, as company value is often tied to future drug development and commercialization success and can influence investor sentiment.

Comparison to Industry Standards

• Insider buying activity is a common occurrence across industries and is generally interpreted as a positive signal, aligning management's interests with shareholders.
• While the specific amounts and prices are unique to Immuneering Corp and Benjamin J. Zeskind, the act of a CEO increasing their stake is consistent with positive insider sentiment observed in other companies where management believes the stock is undervalued or has significant growth potential.
• No specific comparable companies, projects, or results are mentioned in this Form 4 to provide a direct quantitative comparison of results.

Related Party Transactions

• The Benjamin J. Zeskind 2020 Family Trust, where Lisa Schwartz, Dr. Zeskind's spouse, serves as sole trustee, holds 894,927 shares indirectly for Benjamin J. Zeskind.

Stakeholder Impact

• Shareholders: The purchases by the CEO may be viewed as a positive signal, potentially increasing investor confidence and demand for the stock, as it suggests management believes the stock is a good investment.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Recommendation

Keywords

Immuneering Corp, IMRX, Benjamin J. Zeskind, Insider Trading, Stock Purchase, CEO, Director, 10% Owner, Class A Common Stock, SEC Form 4